AIMI | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

71.79%

1 Month

-28.13%

3 Months

-28.13%

6 Months

-28.13%

1 Year

-28.13%

2 Year

-28.13%

Key data

Stock price

$0.07

P/E Ratio

N/A

DAY RANGE

$0.05 - $0.09

EPS

N/A

52 WEEK RANGE

$0.03 - $0.36

52 WEEK CHANGE

-$28.13

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$721,947

AVERAGE 30 VOLUME

$1,079,433

Company detail

CEO: Thomas K. Equels
Region: US
Website: aimimmuno.com
Employees: 20
IPO year: 1996

Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

AIM ImmunoTech Inc. focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS) It is also developing Ampligen for the. treatment of renal cell carcinoma, malignant melanoma,. non-small cell lung, ovarian, breast,. breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis

AIMI - AIM ImmunoTech Inc.